Korro Bio, Inc. cotiza a 8.81 USD y tiene una capitalización bursátil de $130M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -1237.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.07 | $-1.69 | $-1.65 |
| Estimado | $-1.26 | $-1.28 | $-1.98 | $-2.14 |
| Sorpresa | — | +16.4% | +14.6% | +22.9% |
| Métrica | KRRO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1906.4% | -38.6% | -1867.8% |
| Net Margin | -1834.5% | -33.6% | -1800.9% |
| FCF Margin | -1237.2% | -13.9% | -1223.3% |
| ROE | -228.0% | -40.4% | -187.6% |
| ROA | -103.3% | -32.0% | -71.3% |
| Current Ratio | 6.90 | 2.84 | +4.06 |
| Debt / Equity | — | 0.28 | — |